Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort
Background and aims. Patients with Myasthenia gravis (MG) are considered vulnerable as they may present with respiratory muscle weakness and because they are on immunosuppressive treatment; thereby, COVID-19 may have a detrimental effect on these patients. Vaccines against COVID-19 are currently ava...
Saved in:
Main Authors: | Antonino Lupica (Author), Vincenzo Di Stefano (Author), Salvatore Iacono (Author), Antonia Pignolo (Author), Martina Quartana (Author), Andrea Gagliardo (Author), Brigida Fierro (Author), Filippo Brighina (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Autoantibody of NRIP, a novel AChR‐interacting protein, plays a detrimental role in myasthenia gravis
by: Li‐Kai Tsai, et al.
Published: (2021) -
Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review
by: Waheed W, et al.
Published: (2022) -
Juvenile Generalized Myasthenia Gravis With AChR and MuSK Antibody Double Positivity: A Case Report With a Review of the Literature
by: XiuShan Ge, et al.
Published: (2022) -
Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review [Erratum]
by: Waheed W, et al.
Published: (2022) -
Therapeutic Plasma Exchange in AChR-Ab Positive Generalized Myasthenia Gravis: A Real World Study About Its Early Response
by: Chen J, et al.
Published: (2024)